Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
A video roundup of the week’s top industry news stories.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
Contract Pharma Stream offers a centralized destination where users can watch expert-led sessions anytime, anywhere
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
650 Cliffside Drive, San Dimas, CA, 91773, US
The acquisition adds gamgertamig to Gilead’s inflammation portfolio and will be the foundation of Lakefront’s clinical development pipeline.
By: Charlie Sternberg
Adds next-generation ADC assets and a platform designed to maximize patient benefit through more selective delivery of diverse payloads to tumors.
The acquisition expands Gilead’s ADC capabilities by adding next-generation assets and platforms.
Aims to maximize the long-term potential of anito-cel, a potentially transformative treatment for patients with multiple myeloma.
Wettan has held increasingly senior legal leadership roles within Gilead during her 14-year tenure.
Expands its long-standing partnership with Veeva.
Brings its total investments in U.S. manufacturing and R&D through 2030 to more than $32 billion.
Expands its efforts to support initiatives to help meet the needs of vulnerable key populations across Eastern Europe and Central Asia.
Expands its liver portfolio with CymaBay’s investigational lead product candidate, seladelpar.
Acquisition to add MiroBio’s discovery platform and portfolio of immune inhibitory receptor agonists.
Licenses Jounce’s JTX-1811, a monoclonal antibody targeting tumor-infiltrating T regulatory cells.
Cypralis will have exclusive development and commercialization rights to certain macrocyclic inhibitors
Revenues up 97% driven by Sovaldi sales
Revenues up 11% in the quarter with antiviral combos
Revenues up 10% in the quarter
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
